A Multicenter Phase 3 Confirmatory Trial of Biotherapy Using Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)

Who is this study for? Patients with late stage, complex non-healing diabetic foot ulcers
What treatments are being studied? TTAX01
Status: Completed
Location: See all (16) locations...
Intervention Type: Biological, Other
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

It is hypothesized that application at 4-week or greater intervals of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer (DFU) will, with concomitant management of infection, result in a higher rate of wounds showing complete healing within 25 weeks of initiating therapy, compared with standard care alone. This second confirmatory Phase 3 study examines a population of diabetic foot ulcer patients having adequate perfusion, with or without neuropathy, and a high suspicion of associated osteomyelitis in a complex, high grade wound.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• The subject has signed the informed consent form

• The subject is male or female, at least 18 years of age inclusive at the date of Screening

• The subject has confirmed diagnosis of Type I or Type II diabetes

• The subject's index ulcer is located on the plantar surface, inter digital, heel, lateral or medial surface of the foot

• The subject has an index ulcer with visible margins having an area ≤ 12.0 cm2 when measured by the electronic measuring device at Screening

• The subject's index ulcer extends beyond the dermis, into subcutaneous tissue with evidence of exposed bone, tendon, muscle and/or joint capsule

• The subject presents with history, signs or symptoms leading to a clinical suspicion of osteomyelitis in the opinion of the Investigator supported by positive Probe to Bone (PTB) and any of the following: radiographic (X-ray, Magnetic Resonance Imaging (MRI), or bone scan) or evidence of bone necrosis

• The subject has an Ankle-Brachial Index ≥ 0.7 to ≤ 1.3 or TcPO2 ≥ 40 mmHg on the dorsum of the affected foot, or Great Toe Pressure ≥ 50 mmHg

• The subject is under the care of a physician for the management of Diabetes Mellitus

• The subject is willing to return for all mandatory visits as defined in the protocol

• The subject is willing to follow the instructions of the trial Investigator

Locations
United States
Alabama
LakeView Clinical Research
Guntersville
Arizona
Banner University Medical Center Tucson
Tucson
California
Clemente Clinical Research
Los Angeles
VA Northern California Health Care System
Mather
CureCentric
Palmdale
PIH Health
Whittier
Florida
Midland Florida Clinical Research Center
Deland
Delray Physician Care Center
Delray Beach
Illinois
Gateway Clinical Trials, LLC
O'fallon
Massachusetts
Beth Israel Deaconess Medical Center
Boston
New Jersey
Curalta Foot and Ankle
Westwood
Nevada
Reno Orthopedic Clinic
Reno
Ohio
Cutting Edge Research, LLC
Circleville
Texas
University of Texas Southwestern Medical Center
Dallas
Advantage Foot Care of Houston
Houston
Biolife Genetics Research
Houston
Time Frame
Start Date: 2020-11-20
Completion Date: 2025-03-24
Participants
Target number of participants: 106
Treatments
Experimental: TTAX01
TTAX01 plus standard of care
Other: Control
Standard care alone
Related Therapeutic Areas
Sponsors
Leads: BioTissue Holdings, Inc

This content was sourced from clinicaltrials.gov